Ken Griffin Tg Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 185,600 shares of TGTX stock, worth $5.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

185,600

Previous 220,700 15.9%

Holding current value

$5.74 Million

Previous $3.36 Million 1.64%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$13.32 - $19.19 $246,966 - $355,801	-18,541 Reduced 0.99%	1,859,792 $33.1 Million
Q1 2024 May 15, 2024	BUY	$13.02 - $21.3 $18.4 Million - $30.1 Million	1,413,871 Added 304.41%	1,878,333 $28.6 Million
Q4 2023 Feb 14, 2024	BUY	$6.68 - $18.81 $535,408 - $1.51 Million	80,151 Added 20.86%	464,462 $7.93 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $1.71 Million - $5.43 Million	204,942 Added 114.26%	384,311 $3.21 Million
Q2 2023 Aug 14, 2023	SELL	$15.48 - $35.0 $13.8 Million - $31.1 Million	-888,876 Reduced 83.21%	179,369 $4.46 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $7.34 Million - $13.9 Million	717,145 Added 204.26%	1,068,245 $16.1 Million
Q4 2022 Feb 14, 2023	SELL	$5.01 - $11.83 $6.07 Million - $14.3 Million	-1,212,275 Reduced 77.54%	351,100 $4.15 Million
Q3 2022 Nov 14, 2022	SELL	$4.57 - $8.4 $704,095 - $1.29 Million	-154,069 Reduced 8.97%	1,563,375 $9.26 Million
Q2 2022 Aug 15, 2022	BUY	$3.74 - $10.66 $2.4 Million - $6.83 Million	640,516 Added 59.48%	1,717,444 $7.3 Million
Q1 2022 May 16, 2022	BUY	$7.81 - $20.45 $8.07 Million - $21.1 Million	1,033,607 Added 2385.93%	1,076,928 $10.2 Million
Q4 2021 Feb 14, 2022	SELL	$15.2 - $35.51 $1.76 Million - $4.12 Million	-116,012 Reduced 72.81%	43,321 $823,000
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $1.62 Million - $3.02 Million	74,608 Added 88.06%	159,333 $5.3 Million
Q2 2021 Aug 16, 2021	SELL	$32.5 - $48.96 $75,140 - $113,195	-2,312 Reduced 2.66%	84,725 $3.29 Million
Q1 2021 May 17, 2021	SELL	$41.61 - $54.3 $24.6 Million - $32.1 Million	-591,729 Reduced 87.18%	87,037 $4.2 Million
Q4 2020 Feb 16, 2021	BUY	$25.27 - $54.9 $4.41 Million - $9.58 Million	174,554 Added 34.62%	678,766 $35.3 Million
Q3 2020 Nov 16, 2020	BUY	$18.49 - $27.24 $9,818 - $14,464	531 Added 0.11%	504,212 $13.5 Million
Q2 2020 Aug 14, 2020	SELL	$8.9 - $21.84 $14.9 Million - $36.6 Million	-1,677,036 Reduced 76.9%	503,681 $9.81 Million
Q1 2020 May 15, 2020	BUY	$7.14 - $15.99 $8.54 Million - $19.1 Million	1,196,536 Added 121.58%	2,180,717 $21.5 Million
Q4 2019 Feb 14, 2020	BUY	$5.1 - $11.2 $2.66 Million - $5.83 Million	520,890 Added 112.43%	984,181 $10.9 Million
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $1.91 Million - $3.19 Million	354,967 Added 327.69%	463,291 $2.6 Million
Q2 2019 Aug 14, 2019	BUY	$6.27 - $8.65 $441,088 - $608,518	70,349 Added 185.25%	108,324 $937,000
Q1 2019 May 15, 2019	SELL	$4.02 - $8.04 $601,846 - $1.2 Million	-149,713 Reduced 79.77%	37,975 $0
Q4 2018 Feb 14, 2019	SELL	$3.44 - $5.76 $757,343 - $1.27 Million	-220,158 Reduced 53.98%	187,688 $769,000
Q3 2018 Nov 13, 2018	BUY	$5.15 - $14.0 $997,539 - $2.71 Million	193,697 Added 90.45%	407,846 $0
Q2 2018 Aug 10, 2018	BUY	$12.5 - $15.0 $302,925 - $363,510	24,234 Added 12.76%	214,149 $0
Q1 2018 May 11, 2018	BUY	$8.7 - $16.8 $745,320 - $1.44 Million	85,669 Added 82.18%	189,915 $2.7 Million
Q4 2017 Feb 09, 2018	SELL	$7.35 - $12.3 $50,119 - $83,873	-6,819 Reduced 6.14%	104,246 $855,000
Q3 2017 Nov 09, 2017	BUY	$10.0 - $12.7 $1.11 Million - $1.41 Million	111,065	111,065 $1.32 Million

Others Institutions Holding TGTX

# of Institutions

326

Shares Held

93.8M

Call Options Held

1.82M

Put Options Held

1.37M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.49B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account